Jasper Therapeutics merges with Kira Pharmaceuticals, divests Tavneos rival to Mirador

Jasper Therapeutics announced a merger with Nasdaq‑listed Kira Pharmaceuticals, positioning the combined company for a fresh strategic direction. The deal follows a difficult period for Jasper, which cut its workforce in half and saw its chief medical officer depart after a problematic batch of its anti‑KIT antibody, briquilimab, disrupted a phase 1/2 trial in spontaneous urticaria and led to the suspension of an asthma program.

Kira brings a differentiated complement portfolio that includes dual‑mechanism agents and long‑acting complement inhibitors, which Jasper’s CEO Jeet Mahal highlighted as a key strength of the transaction. Mahal will lead the merged entity, emphasizing the robust pipeline and the potential to advance important medicines for patients.

As part of the restructuring, Jasper is offloading its Tavneos competitor to Mirador Therapeutics, further streamlining its focus on the new combined pipeline.